| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia SG O'Brien, F Guilhot, RA Larson, I Gathmann, M Baccarani, F Cervantes, ... New England Journal of Medicine 348 (11), 994-1004, 2003 | 4727 | 2003 |
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ... New England Journal of Medicine 355 (23), 2408-2417, 2006 | 4464 | 2006 |
| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ... Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013 | 2650 | 2013 |
| Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia G Saglio, DW Kim, S Issaragrisil, P Le Coutre, G Etienne, C Lobo, ... New England Journal of Medicine 362 (24), 2251-2259, 2010 | 2147 | 2010 |
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ... Journal of clinical oncology 27 (35), 6041-6051, 2009 | 1891 | 2009 |
| Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet M Baccarani, G Saglio, J Goldman, A Hochhaus, B Simonsson, ... Blood 108 (6), 1809-1820, 2006 | 1843 | 2006 |
| Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia TP Hughes, J Kaeda, S Branford, Z Rudzki, A Hochhaus, ML Hensley, ... New England Journal of Medicine 349 (15), 1423-1432, 2003 | 1618 | 2003 |
| Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL … T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ... Blood 108 (1), 28-37, 2006 | 1546 | 2006 |
| Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia KG Roberts, Y Li, D Payne-Turner, RC Harvey, YL Yang, D Pei, ... New England journal of medicine 371 (11), 1005-1015, 2014 | 1542 | 2014 |
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ... Leukemia 34 (4), 966-984, 2020 | 1405 | 2020 |
| Long-term outcomes of imatinib treatment for chronic myeloid leukemia A Hochhaus, RA Larson, F Guilhot, JP Radich, S Branford, TP Hughes, ... New England Journal of Medicine 376 (10), 917-927, 2017 | 1351 | 2017 |
| A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ... New England Journal of Medicine 369 (19), 1783-1796, 2013 | 1304 | 2013 |
| BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros CG Mullighan, CB Miller, I Radtke, LA Phillips, J Dalton, J Ma, D White, ... Nature 453 (7191), 110-114, 2008 | 1231 | 2008 |
| Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia A Hochhaus, SG O'brien, F Guilhot, BJ Druker, S Branford, L Foroni, ... Leukemia 23 (6), 1054-1061, 2009 | 1159 | 2009 |
| Dynamics of chronic myeloid leukaemia F Michor, TP Hughes, Y Iwasa, S Branford, NP Shah, CL Sawyers, ... Nature 435 (7046), 1267-1270, 2005 | 999 | 2005 |
| Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding … S Branford, Z Rudzki, S Walsh, I Parkinson, A Grigg, J Szer, K Taylor, ... Blood 102 (1), 276-283, 2003 | 999 | 2003 |
| Lin28 promotes transformation and is associated with advanced human malignancies SR Viswanathan, JT Powers, W Einhorn, Y Hoshida, TL Ng, S Toffanin, ... Nature genetics 41 (7), 843-848, 2009 | 965 | 2009 |
| International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed … M Deininger, SG O'Brien, F Guilhot, JM Goldman, A Hochhaus, ... Blood 114 (22), 1126, 2009 | 958 | 2009 |
| Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial A Hochhaus, G Saglio, TP Hughes, RA Larson, DW Kim, S Issaragrisil, ... Leukemia 30 (5), 1044-1054, 2016 | 934 | 2016 |
| High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute … S Branford, Z Rudzki, S Walsh, A Grigg, C Arthur, K Taylor, R Herrmann, ... Blood, The Journal of the American Society of Hematology 99 (9), 3472-3475, 2002 | 915 | 2002 |
